Biogen Price to Free Cash Flow Ratio 2010-2022 | BIIB

Historical price to free cash flow ratio values for Biogen (BIIB) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biogen Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-08-12 220.99 13.90
2022-06-30 203.94 $15.90 12.83
2022-03-31 210.60 $18.87 11.16
2021-12-31 239.92 $22.61 10.61
2021-09-30 282.99 $13.97 20.26
2021-06-30 346.27 $16.15 21.44
2021-03-31 279.75 $20.42 13.70
2020-12-31 244.86 $23.59 10.38
2020-09-30 283.68 $36.52 7.77
2020-06-30 267.55 $38.34 6.98
2020-03-31 316.38 $35.88 8.82
2019-12-31 296.73 $35.03 8.47
2019-09-30 232.82 $33.42 6.97
2019-06-30 233.87 $32.23 7.26
2019-03-31 236.38 $27.19 8.69
2018-12-31 300.92 $26.39 11.40
2018-09-30 353.31 $24.54 14.40
2018-06-30 290.24 $23.09 12.57
2018-03-31 273.82 $23.14 11.83
2017-12-31 318.57 $17.29 18.42
2017-09-30 313.12 $17.74 17.65
2017-06-30 271.36 $14.87 18.25
2017-03-31 273.42 $14.21 19.24
2016-12-31 261.39 $18.15 14.40
2016-09-30 288.53 $16.35 17.65
2016-06-30 222.89 $15.56 14.32
2016-03-31 239.95 $15.53 15.45
2015-12-31 282.37 $14.17 19.93
2015-09-30 268.35 $13.01 20.62
2015-06-30 372.33 $13.66 27.25
2015-03-31 389.19 $13.67 28.46
2014-12-31 312.88 $11.19 27.96
2014-09-30 304.92 $11.03 27.64
2014-06-30 290.63 $9.92 29.30
2014-03-31 281.93 $8.41 33.53
2013-12-31 257.69 $8.81 29.26
2013-09-30 221.92 $7.29 30.46
2013-06-30 198.36 $6.86 28.91
2013-03-31 177.54 $3.40 52.18
2012-12-31 134.91 $6.78 19.90
2012-09-30 137.53 $6.64 20.73
2012-06-30 133.08 $6.69 19.91
2012-03-31 116.14 $9.29 12.51
2011-12-31 101.44 $6.20 16.36
2011-09-30 85.86 $5.83 14.72
2011-06-30 98.55 $5.53 17.81
2011-03-31 67.72 $5.51 12.30
2010-12-31 61.80 $5.70 10.85
2010-09-30 51.73 $5.20 9.95
2010-06-30 43.74 $4.16 10.50
2010-03-31 52.90 $3.33 15.90
2009-12-31 49.31 $3.14 15.70
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $31.667B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.991B 9.65
GSK (GSK) United Kingdom $72.663B 8.73
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.304B 18.93
Biohaven Pharmaceutical Holding (BHVN) United States $10.553B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.041B 0.00
Arcus Biosciences (RCUS) United States $1.868B 36.45
Myovant Sciences (MYOV) United Kingdom $1.698B 0.00
Emergent Biosolutions (EBS) United States $1.490B 8.64
Zymeworks (ZYME) Canada $0.404B 0.00
Enzo Biochem (ENZ) United States $0.131B 0.00
Gelesis Holdings (GLS) United States $0.117B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00